Home > Dermatology > SPIN 2022 > Psoriasis: The Beat Goes On > All patients with GPP benefit from IL-36 inhibitor therapy

All patients with GPP benefit from IL-36 inhibitor therapy

Conference
SPIN 2022
Trial
Phase 2, Effisayil 1
Doi
https://doi.org/10.55788/dfae1d42
The IL-36 receptor antibody spesolimab showed to be effective in all patients with generalised pustular psoriasis (GPP), independent of age, sex, race, BMI, IL-36RN mutation status, and different physician global assessment scores. This was the result of a subgroup analysis of the phase 2 trial Effisayil 1. In the 12-week randomised, placebo-controlled, phase 2 Effisayil 1 trial (NCT03782792), a single intravenous dose of the anti-IL-36 receptor antibody spesolimab led to a higher incidence of skin clearance compared with placebo: 54% of patients in the spesolimab group versus 6% in the placebo group achieved complete clearance of pustules, corresponding to a general pustular psoriasis global assessment (GPPGA) pustulation subscore of 0 (primary endpoint) [1]. The key secondary endpoints were a GPPGA total score of 0 ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on